Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
84-96-8
Molecular formula
C18H22N2S
Molecular weight
298.4 g/mol
Drug class
First-generation phenothiazine antihistaminesedative and antipruritic agent
Mechanism of action
Antagonises peripheral and central histamine H1 receptors. Additional anticholinergic, antidopaminergic and sedative effects may contribute to its clinical actions; receptor selectivity varies by dose.
Indications / reported uses
Symptomatic treatment of allergic disorders including pruritus and urticaria in product-authorised settings
Short-term symptomatic treatment of severe pruritus and selected sleep-related or premedication uses only where covered by the specific formulation and national product information
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Alimemazine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Alimemazine Permitted Daily Exposure (PDE) report (the Alimemazine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Alimemazine Occupational Exposure Limit (OEL) report (the Alimemazine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.